63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

85 trials found

diseases per page:

Showing 1 to 10 of 85 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05653219 (ClinicalTrials.gov)	February 2, 2023	23/11/2022	A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopagin Primary Immu ...	A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltromb ...	Primary Immune Thrombocytopenia	Biological: Ianalumab;Drug: Eltrombopag;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	150	Phase 3	Czechia;Hungary;Korea, Republic of;Singapore;United Kingdom
2	EUCTR2022-001627-32-ES (EUCTR)	23/01/2023	01/11/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
3	EUCTR2022-001627-32-NL (EUCTR)	29/12/2022	31/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
4	EUCTR2022-001627-32-CZ (EUCTR)	05/12/2022	20/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	Singapore;United States;Czechia;Malaysia;Thailand;Austria;Netherlands;China;Korea, Republic of;Franc ...
5	NCT05583838 (ClinicalTrials.gov)	November 22, 2022	12/10/2022	A Randomized Trial Comparing Optimized rhTPO Treatment With EltrombopagTreatment in Pre-treated ITP ...	Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus EltrombopagTreatment in Previo ...	Previously Treated Primary Immune Thrombocytopenia	Drug: rhTPO;Drug: Eltrombopag	Institute of Hematology & Blood Diseases Hospital	The Second Hospital of Hebei Medical University;Xijing Hospital;The Affiliated Hospital of Inner Mon ...	Recruiting	18 Years	85 Years	All	175	Phase 4	China
6	NCT04812483 (ClinicalTrials.gov)	September 1, 2022	1/3/2021	Immunomodulation With Eltrombopag in ITP	Immunomodulation in Young and Midlife Adults With Newly Diagnosed Primary Immune Thrombocytopenia (I ...	Primary Immune Thrombocytopenia (ITP)	Drug: Eltrombopag (Revolade®);Drug: standard therapy (without eltrombopag): HD-DXM	University Children's Hospital Basel	Stiftung zur Förderung medizinischer und biologischer Forschung;Novartis Pharmaceuticals;University ...	Recruiting	18 Years	55 Years	All	24	Phase 2	Switzerland
7	NCT05369377 (ClinicalTrials.gov)	June 1, 2022	6/5/2022	Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia	Zanubrutinib and Eltrombopagas Second-line Treatment for Patients With Immune Thrombocytopenia: a Mu ...	Immune Thrombocytopenia	Drug: Zanubrutinib;Drug: Eltrombopag	Peking University People's Hospital	Beijing Hospital;The Sixth Medical Center of PLA General Hospital;Beijing Aerospace General Hospital ...	Not yet recruiting	18 Years	70 Years	All	150	Phase 2	China
8	ChiCTR2000040991	2022-03-02	2020-12-16	Cyclosporine A combined with eltrombopagin the treatment for primary immune thrombocytopenia: a pros ...	Cyclosporine A combined with eltrombopagin the treatment for primary immune thrombocytopenia: a pros ...	primary immune thrombocytopenia	experimental group:Cyclosporine A combined with eltrombopag;	The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Recruiting	18	75	Both	experimental group:28;	Phase 4	China
9	NCT04917679 (ClinicalTrials.gov)	September 1, 2020	1/12/2020	Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP	EltrombopagPlus Diacerein vs Eltrombopagin Adult Primary Immune Thrombocytopenia: a Multicenter Rand ...	Thrombocytopenia	Drug: Eltrombopag plus diacerein;Drug: Eltrombopag	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	N/A	All	100	Phase 2	China
10	NCT04518475 (ClinicalTrials.gov)	August 10, 2020	12/8/2020	EltrombopagCombining Rituximab Versus Eltrombopagin the Management of Primary Immune Thrombocytopeni ...	A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of EltrombopagCombini ...	Primary Immune Thrombocytopenia (ITP)	Drug: eltrombopag combining rituximab;Drug: eltrombopag	Institute of Hematology & Blood Diseases Hospital	The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical U ...	Recruiting	18 Years	60 Years	All	224	Phase 4	China

First Previous1 2 3 4 5…9Next Last